Carregant...
Fitxers
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/220168
Safety and efficacy of tinostamustine in a subpopulation of patients with relapsed/refractory Hodgkin lymphoma from a phase I trial
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
A significant unmet need remains for patients with Hodgkin lymphoma (HL) who fail to respond to first-line treatment or experience an early relapse. Tinostamustine, a novel alkylating deacetylase inhibitor, inhibits tumor cell growth and slows disease progression in models of hematological malignancies and solid tumors. This was a Phase I, multicenter, open-label, two-stage trial investigating the safety and efficacy of tinostamustine in patients ≥ 18 years with relapsed/refractory (R/R) hematological malignancies, including HL. Stage 1 involved dose-escalation to determine the maximum tolerated dose (MTD) of tinostamustine, optimal infusion time and recommended Phase II dose (RP2D). Stage 2 confirmed the safety and efficacy of the RP2D in expansion cohorts of selected R/R hematological malignancies. Ten patients with heavily pre-treated HL entered dose-escalation, with nine patients experiencing treatment-emergent adverse events (TEAEs) considered to be related to study treatment-primarily hematological toxicities. MTD was 100 mg/m2 tinostamustine over 60 min and signals of efficacy were observed for patients with HL. In Stage 2, all 20 patients with HL experienced ≥ 1 TEAE, which were principally hematological or gastrointestinal. There were no tinostamustine-related deaths in either stage of the study. Overall response rate in Stage 2 was 37% (2 complete responses, 5 partial responses; 95% confidence interval [CI]: 16%, 62%) and median progression-free survival 3.8 months (95% CI: 2.2-9.4 months). Tinostamustine is a promising new therapeutic approach for the treatment of patients with R/R classical HL with limited options. This study demonstrates a predictable and manageable safety profile with signals of efficacy.
Matèries (anglès)
Citació
Citació
SUREDA, Anna, PINTO, Antonio, GHESQUIÈRES, Hervé, MORSCHHAUSER, Franck, TOURNILHAC, Olivier, MUTSAERS, Pim, ZIJLSTRA, Josée m., DE FILIPPI, Rosaria, HILGIER, Kasia, MANAMLEY, Nick, JANIK, Tomas, ZINZANI, Pier luigi. Safety and efficacy of tinostamustine in a subpopulation of patients with relapsed/refractory Hodgkin lymphoma from a phase I trial. _Hematological Oncology_. 2025. Vol. 43, núm. 1. [consulta: 21 de gener de 2026]. ISSN: 0278-0232. [Disponible a: https://hdl.handle.net/2445/220168]